Karyopharm Therapeutics
KPTI
78 hedge funds and large institutions have $704M invested in Karyopharm Therapeutics in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 10 closing their positions.
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
126% more capital invested
Capital invested by funds: $311M → $704M (+$393M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 18
30% more funds holding
Funds holding: 60 → 78 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$69.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.1M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$8.33M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$6.46M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.98M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.97M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$1.44M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GSC
76
Ground Swell Capital
Folly Beach,
South Carolina
| $6K | +$4.19K | +9 | New |
|
77
Citigroup
New York
| $5K | -$1.86K | -4 | -36% |
|
78
BNP Paribas Financial Markets
Paris,
France
| $1.58K | – | – | – |
|
|
79
Principal Financial Group
Des Moines,
Iowa
| – | -$1.98M | -4,267 | Closed |
|
|
EI
80
EAM Investors
Solana Beach,
California
| – | -$1.97M | -4,253 | Closed |
|
|
81
UBS AM
Chicago,
Illinois
| – | -$1.44M | -3,107 | Closed |
|
|
RFC
82
Russell Frank Company
Seattle,
Washington
| – | -$1.05M | -2,746 | Closed |
|
83
Ameriprise
Minneapolis,
Minnesota
| – | -$845K | -1,825 | Closed |
|
|
FM
84
Forward Management
San Francisco,
California
| – | -$396K | -1,439 | Closed |
|
|
ARTA
85
A.R.T. Advisors
New York
| – | -$471K | -1,018 | Closed |
|
|
AI
86
Analytic Investors
Los Angeles,
California
| – | -$273K | -589 | Closed |
|
|
BJ
87
BlackRock Japan
Tokyo,
Japan
| – | -$61K | -131 | Closed |
|
|
TRCT
88
Tower Research Capital (TRC)
New York
| – | -$4.19K | -9 | Closed |
|
KPTI Hedge Fund Activity: Q2 2014 in Review
78 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2014, worth a combined $704M — up 126% from $311M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KPTI positions and 10 closed out — a net gain of 19 holders — while 30 added to existing stakes and 18 trimmed.
The largest buyer was Franklin Resources, adding an estimated $69.3M. The largest seller was Foresite Capital Management I, cutting an estimated $6.46M.
- 78 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2014, up from 60 in Q1 2014.
- Funds reported $704M of Karyopharm Therapeutics stock for Q2 2014, up 126% quarter-over-quarter.
- 29 funds opened new Karyopharm Therapeutics positions in Q2 2014 and 10 closed out, a net change of +19 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2014 was Franklin Resources, an estimated $69.3M added.
- The largest Karyopharm Therapeutics seller in Q2 2014 was Foresite Capital Management I, an estimated $6.46M sold.
Based on aggregated 13F filings for Q2 2014.